Focus on Diabetes Care

Back to articles

Sulfonylureas as second-line agents increase the risk of adverse outcomes

September 11, 2018
  • Advising on this article:
  • Charles D. Ponte

KEY POINT

Adding sulfonylurea to metformin therapy or switching metformin to a sulfonylurea in patients with type 2 diabetes resulted in an increased risk of myocardial infarction (MI), all-cause mortality, and severe hypoglycemia compared with metformin monotherapy, according to results of an observational study published in BMJ.

SOURCES

Douros A, et al. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: Population based cohort study. BMJ. 2018;[Epub ahead of print]. 

D’Agostino L, et al. Sulfonylureas as second line treatment for type 2 diabetes. BMJ. 2018;[Epub ahead of print]. 

American Diabetes Association. Standards of Medical Care in Diabetes–2018. Accessed August 10, 2018.

 

Recent Articles

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

More info

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.